Research Article

The Natural Carotenoid Crocetin and the Synthetic Tellurium Compound AS101 Protect the Ovary against Cyclophosphamide by Modulating SIRT1 and Mitochondrial Markers

Giovanna Di Emidio,1 Giulia Rossi,1 Isabelle Bonomo,2 Gonzalo Luis Alonso,3 Roberta Sferra,4 Antonella Vetuschi,4 Paolo Giovanni Artini,5 Alessandro Provenzani,2 Stefano Falone,1 Gaspare Carta,1 Anna Maria D’Alessandro,1 Fernanda Amicarelli,1,6 and Carla Tatone1

1Department of Life, Health and Environmental Sciences, University of L’Aquila, L’Aquila, Italy
2Centre For Integrative Biology (CIBIO), Università degli Studi di Trento, Trento, Italy
3School of Agricultural Engineering, University of Castilla-La Mancha, Albacete, Spain
4Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
5Department of Reproductive Medicine and Child Development, Division of Obstetrics and Gynaecology, University of Pisa, Pisa, Italy
6Institute of Translational Pharmacology (IFT), National Council of Research (CNR), L’Aquila, Italy

Correspondence should be addressed to Carla Tatone; carla.tatone@univaq.it

Received 28 July 2017; Accepted 1 October 2017; Published 15 November 2017

Copyright © 2017 Giovanna Di Emidio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cancer therapies are associated with increased infertility risk due to accelerated reproductive aging. Oxidative stress (OS) is a potential mechanism behind ovarian toxicity by cyclophosphamide (CPM), the most ovotoxic anticancer drug. An important sensor of OS is SIRT1, a NAD+-dependent deacetylase which regulates cellular defence and cell fate. This study investigated whether the natural carotenoid crocetin and the synthetic compound AS101 protect the ovary against CPM by modulating SIRT1 and mitochondrial markers. We found that the number of primordial follicles of female CD1 mice receiving crocetin plus CPM increased when compared with CPM alone and similar to AS101, whose protective effects are known. SIRT1 increased in CPM mouse ovaries revealing the occurrence of OS. Similarly, mitochondrial SIRT3 rose, whilst SOD2 and the mitochondrial biogenesis activator PGC1-α decreased, suggesting the occurrence of mitochondrial damage. Crocetin and AS101 administration prevented SIRT1 burst suggesting that preservation of redox balance can help the ovary to counteract ovarian damage by CPM. Decreased SIRT3 and increased SOD2 and PGC1-α in mice receiving crocetin or AS101 prior to CPM provide evidence for mitochondrial protection. Present results improve the knowledge of ovarian damage by CPM and may help to develop interventions for preserving fertility in cancer patients.

1. Introduction

Novel management strategies have led to increased rates of cancer survivors throughout the past three decades highlighting the need of posttreatment care to improve the patient’s quality of life [1]. For females, a serious long-term side effect of cancer therapies is the increased infertility risk due to accelerated reproductive aging leading to premature ovarian failure (POF) [2]. Hence, fertility preservation has been integrated into oncology practice giving rise to oncofertility, a new discipline that bridges oncology and reproductive research [3]. Current strategies are based mainly on assisted reproductive technologies (i.e., oocyte-embryo cryopreservation and ovarian tissue cryopreservation/transplantation)
that are suitable only for few categories of patients or are still experimental [1]. Suppression of the pituitary-gonadal axis via GnRH analogue administration has been so far the most feasible intervention although results of recent clinical trials are contradictory [4–6]. One of the possible reasons for limited progress in the field is the partial understanding of the mechanistic events that could be targeted to provide protection or repair from ovotoxicity (reviewed by [7, 8]).

Similar to women, studies in rodents revealed that the predominant effect of anticancer cytotoxic treatments is the total or partial loss of the finite pool of dormant oocytes in the primordial follicles at concentrations relevant to human exposures [9–11].

Clinically, the most ovotoxic drugs are the alkylating agents including cyclophosphamide (CPM). This drug is widely used for the treatment of cancers affecting females in their childhood or reproductive age, including breast cancer [5, 12]. It is also used as an immunosuppressant for autoimmune diseases and multiple sclerosis and preventing organ transplant rejection [13–15]. CPM requires hepatic bioactivation to form the active metabolite phosphoramide mustard (PM) that covalently binds to DNA, inducing DNA-DNA, DNA-protein crosslinks, and DNA double-strand breaks (DSB). Both oocytes and granulosa cells show these types of DNA damage following in vitro exposure of ovaries and cells [16, 17]. The activation of an ovarian DNA damage repair response has been reported in terms of early upregulation of specific genes including ATM (ataxia telangiectasia mutated) in neonatal rat ovaries exposed to PM. This response was associated with increased levels of proapoptotic genes and follicle loss by apoptosis [18, 19]. In addition to apoptosis, CPM-induced DNA damage may also cause activation of follicle dormancy by stimulating the PI3K/PTEN/AKT signalling pathway. The upregulation of AKT signalling would lead to phosphorylation/inhibition of FOXO3a transcription factor in primordial follicles and subsequent disruption of the regulatory mechanism underlying dormancy of primordial follicles [20, 21]. In vivo administration of AS101 (ammonium trichloro(dioxoethylene-α,α,α-triethyl)dilaurate), an immunomodulator with antitumor effects [22], inhibits AKT phosphorylation/activation induced by CPM and prevents the loss of primordial follicles. Beneficial effects on growing follicles were also observed [20].

A further potential mechanism behind CPM ovarian toxicity is oxidative stress (OS) (reviewed by [23, 24]). In a human granulosa cell line, exposure to a pre-activated CPM metabolite results in depletion of glutathione (GSH), a crucial cellular antioxidant, a rise in reactive oxygen species (ROS) and apoptosis. Consistently, GSH exposure reduces CPM-induced granulosa cell toxicity [25]. Moreover, in vivo administration of CPM has been associated with low GSH content, reduced SOD2 (Superoxide dismutase 2) activity, and increased lipid peroxidation in rat ovaries [26, 27]. Oxidative stress is thought to arise from biotransformation/detoxification of PM as described by Madden and Keating [28] in in vitro ovarian models.

An important sensor of cell redox state is SIRT1, one of the seven members of the mammalian sirtuin family, NAD+-dependent enzymes with deacetylase and/or mono-ADP-ribosyl transferase activity [29–33]. By its numerous targets, SIRT1 orchestrates cellular defence and repair mechanisms and controls cell fate avoiding survival of damaged cells [34]. Mouse oocytes upregulate SIRT1 gene to cope with OS supporting a pivotal role for this protein in the early adaptive response to OS [35, 36]. In many tissues, SIRT1 abundance can be regulated by modulating the mRNA stability by the RNA-binding protein HuR (Hu antigen R). Indeed, HuR stabilises SIRT1 transcripts and promotes their polyribosomal engagement for active translation [37]. An important SIRT1 substrate is PGC1-α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), an activator of mitochondrial biogenesis and a key regulator of mitochondrial gene expression required to meet energetic demands during cellular stresses [38]. These activities under stress conditions are also regulated by the mitochondrial sirtuin, SIRT3, throughout a complex network [39–41].

Although OS has been proposed as an important phenomenon involved in CPM ovarian toxicity, the efficacy of in vivo antioxidant interventions has been poorly investigated [26, 27]. Systemic treatment with some carotenoids has been largely demonstrated to protect nonmalignant tissues against CPM toxicity by promoting antioxidant and anti-inflammatory effects [42–46]. Crocetin (8,8′-diapocarotenedioic acid) belongs to the bioactive family of carotenoids derived from the stigmas of Crocus sativus (saffron spice) and well-known in traditional medicine [47, 48]. Crocetin is known to act as an effective free radical scavenger and lipid peroxidation inhibitor. Importantly, it effectively improved antioxidant biomarkers and attenuated inflammatory reaction [49–53]. Furthermore, crocetin is known to exert potent antitumour effects [54–56].

Based on the above observations, this work investigates whether (i) oral administration of the natural carotenoid crocetin prevents gonadotoxicity in female mice; (ii) SIRT1 is involved in the molecular pathways activated in the early ovarian response to CPM; and (iii) the protective effects of crocetin influence SIRT1 expression and mitochondrial toxicity induced by CPM. To address the first point, we tested the ability of crocetin to mitigate CPM-induced follicle loss, primordial follicle activation, and subfertility. To clarify SIRT1 involvement, we relied on a human granulosa cell line previously used to test CPM toxicity [25, 57], prior to investigation on the animal model. To gain knowledge about crocetin efficacy and mechanism of action, the fertoprotective agent AS101, known to protect the mouse ovary against CPM, was also tested [20].

2. Materials and Methods

2.1. Cyclophosphamide, Crocetin, and AS101 Preparation. Cyclophosphamide (CPM) was obtained from Baxter, Rome, Italy. A solution of CPM at a concentration of 25 mg/mL in PBS (pH 7.4) was freshly prepared.

Crocetin isolation was performed by crocetin esters [56] and purified by an internal method of the Verdú Cantó Saffron Spain Company (Novelda, Alicante, Spain). Crocetin quantification was analysed by the reverse-phase HPLC technique. Twenty μL of crocetin aqueous solution (252 mg/L)
was filtered through a 0.45 μm PTFE filter and injected into an Agilent 1200 chromatograph (Palo Alto, CA) operating with a 150 mm × 4.6 mm i.d. and 5 μm Phenomenex (Le Pecq Cedex, France) Luna C18 chromatographic column, at 30°C. Eluents were water (A) and acetonitrile (B) with the following elution gradient: 20% B, 0–5 min; 20–80% B, 5–15 min; 80% B, 15–18 min; and 20% B, 18–30 min. The flow rate was 0.8 mL min⁻¹, and the DAD detector (Hewlett Packard, Waldbronn, Germany) was set at 440 nm for the detection of cis/trans crocetin. Crocetin quantification was estimated using the method based on the extinction coefficient and the related area calculated according to [58, 59].

AS101 was obtained from Tocris Biosciences, Bristol, UK. A solution of AS101 at a concentration of 150 mg/mL in PBS (pH 7.4) was freshly prepared.

2.2. Mice and Study Design. A total of 69 young CD-1 female mice aged 4 to 8 weeks (Charles River Italia s.r.l., Calco, Italy) were used in the present study. All the experiments were carried out in accordance with the guidelines for the care and use of laboratory animals approved by the Animal Care Committee of the University of L’Aquila. Mice were randomly divided into four groups:

(i) CTRL: normal control mice were maintained on a standard laboratory pellet diet and water ad libitum, without administering medicine for 15 consecutive days. On the 15th day, they received a single intraperitoneal injection of 100 μL of PBS.

(ii) CPM: mice were maintained on a standard laboratory pellet diet and water ad libitum, without administering medicine for 15 consecutive days. On the 15th day, they received a single intraperitoneal injection of CPM (100 mg/kg).

(iii) CRO + CPM: mice received crocetin extract (100 mg/kg, [56]) by using a gastric gavage and were allowed free access to a standard laboratory pellet diet and water for 15 consecutive days. On the 15th day, they received a single intraperitoneal injection of 100 μL of CPM (100 mg/kg).

(iv) AS101 + CPM: mice received AS101 (10 μg per mouse, [20]) by intraperitoneal injections on alternate days and were allowed free access to a standard laboratory pellet diet and water for 15 consecutive days. On the 15th day, they received a single intraperitoneal injection of 100 μL of CPM (100 mg/kg).

At 12 h and 24 h after the administration of CPM, three mice of each group were sacrificed by cervical dislocation (in accordance with the provisions of the EEC regulation 86/609), and ovaries were immediately placed into liquid nitrogen and then stored at −80°C for further analysis. The remaining animals were sacrificed 7 days post CPM, and ovaries were fixed in 4% paraformaldehyde (PFA) at 4°C overnight and paraffin-embedded. Ovarian sections of 5 μm were prepared for further analysis.

2.3. Haematoxylin and Eosin Staining and Follicular Classification. Ovarian sections were stained with haematoxylin and eosin (H&E) and analysed under a light microscope for differential follicle counts. Briefly, blind follicle counts were conducted on every fifth section of entire ovaries by two independent researchers. Follicle stage was classified according to [60]. The classification is based on (i) the size of the oocyte in follicles of different stages of development; (ii) the size of the follicle defined by the number of cells constituting the follicular envelope, and (iii) the morphology of the follicle. Primordial follicles are quiescent follicles characterized by a small oocyte, with a diameter of less than 20 μm, with up to 20 follicle cells attached to its surface on the largest cross-section. Growing follicles include primary follicles, characterized by one complete ring of follicle cells (21 to 60 cells on the largest cross-section) that surround a growing oocyte (diameter between 20 and 70 μm); secondary follicles, with two or three layers of follicle cells (61 to 200 cells on the largest cross-section) surrounding a growing oocyte (diameter between 20 and 70 μm); and antral follicles, a fully grown oocyte (diameter 70 μm) surrounded by many layers of follicle cells separated by scattered areas or a cavity containing follicle fluid. Only those follicles in which the nucleus of the oocyte was clearly visible were considered and taken into account. The numbers were then multiplied by 5 in order to obtain an estimate of total follicle numbers per ovary [61].

2.4. Mating Protocol. The mating protocol proposed by Meirow et al. [10] in order to avoid the risk of CPM-related foetal malformations was selected. Briefly, twelve weeks after CPM, female mice from each experimental group were mated with untreated proven fertile males (two females to one male) for 1 week. Then, the females were separated for the duration of pregnancy (21 days) until 3 weeks after the birth of the litter. Females were remated every 8 weeks for a total of three successive mating rounds. The mean number of pups per mouse was counted after each mating round in all experimental groups.

2.5. In Vitro Culture of Granulosa Cells and Proliferation Analysis by BrdU Incorporation. COV434 cells are mitotic human granulosa cells used for in vitro studies of cytotoxic actions of chemotherapy drugs [25, 57, 62]. COV434 cells (Sigma-Aldrich, St. Louis, MO) were cultured in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% foetal bovine serum (FBS) and 1% penicillin/streptomycin and 2 mM L-glutamine. Cultures were maintained at 37°C in a CO₂ incubator with a controlled humidified atmosphere composed of 95% air and 5% CO₂. FBS, DMEM, penicillin/streptomycin, and all other reagents used for cell culture studies were purchased from Euroclone (Pero, Italy). Cells were seeded at a density of 2.5 × 10⁴ cells per well in 96-well plates and exposed to the active CPM metabolite phosphoramidate mustard (PM, Niotech, Bielefeld, Germany) at concentrations ranging from 10 to 100 μM. The effects of PM on cell proliferation were assessed using the Cell Proliferation BrdU ELISA (Roche Applied Science, Mannheim, Germany) according to the manufacturer’s instructions. Briefly, after 60 h, 10 μL of BrdU reagent was
added to each well and the cells were cultured for 12 h at 37 °C. After 72 h of culture, cells were fixed with Carnoy’s fixative (3:1 methanol: glacial acetic acid) for 20 minutes at −20°C. DNA was partially digested with nucleases to allow the antibody to access BrdU; then cells were incubated with a monoclonal antibody to BrdU, followed by incubation with the anti-BrdU antibody labelled with peroxidase. Finally, the peroxidase substrate ABTS was added, in order to obtain a coloured reaction product. The absorbance of the samples was measured at approximately 405 nm with a standard microplate reader (Sunrise, Tecan, Männedorf, Switzerland).

2.6. Quantitative Real-Time PCR. Granulosa cells were exposed to 50 µM PM for 3 h, 6 h, and 12 h, and total RNA was extracted using TRIZOL reagent (Life Technologies-Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer’s instructions. 1 µg of total RNA was retrotranscribed in a final volume of 20 µL using a cDNA Reverse Transcription kit (Life Technologies-Thermo Fisher Scientific). 2 µL of cDNA was used for q-RT-PCRs using aCFX96 Touch™ Real-Time PCR Detection System (Bio-Rad Laboratories, Milan, Italy). Primer sequences were the following: SIRT1: FW 5′-CAGTGTCATGGTTGCTTTTC-3′ and REV 5′-AGGACATCGAGGAATCACCCTG-3′; HuR: FW 5′-GCTATGGGTTGGAACTACGTG-3′ and REV 5′-TGATGTAACAGTGGGCTCTTG-3′; and RNA18S: FW 5′-GCAGCCTAGGAATAATGGAATAG-3′ and REV 5′-TGATGTAACAGTGGGCTCTTG-3′. mRNA levels were detected using a KAPA SYBR® FAST qPCR Master Mix (2X) Kit (KAPA Biosystems, Wilmington, MA, USA) according to the manufacturer’s protocol. Gene expression was normalized to the housekeeping gene RNA 18S. Comparisons in gene expression were calculated using the 2−ΔΔCt method. Two biological replicates were performed, each in technical triplicates.

2.7. Sample Preparation and Western Blot Analysis. Ovarian tissues were homogenized in RIPA buffer by repeated freeze/thaw cycles in liquid nitrogen. After centrifugation (33,000 rpm for 1 h at 4°C), the supernatants were collected for protein analysis. Protein concentration was determined in Tris-buffered saline containing 0.05% Tween 20 (TBS-T). Membranes were blocked overnight with 5% non-fat dry milk (Bio-Rad Laboratories) in TBS-T. Membranes were probed with the following antibodies: rabbit polyclonal anti-SIRT3 (Ab86871, Abcam, Cambridge, UK), mouse monoclonal anti-HuR (SC-71290, Santa Cruz Biotechnology Inc., Dallas, TX, USA), rabbit monoclonal anti-SOD2 (Ab86087, Abcam, 1:1000), rabbit monoclonal anti-β-actin antibody (Ab8226, Abcam; 1:3000) for 1 h at room temperature, followed by incubation with horseradish peroxidase-conjugated anti-rabbit (Ab6721, Abcam, 1:3000) or anti mouse (Ab6728, Abcam, 1:2000) secondary antibody for 1 h at room temperature. After washing, specific immunoreactive complexes were detected by an ECL kit (Life Technologies-Thermo Scientific) and Uvitec Cambridge system (Alliance series, Cambridge, UK). When membrane reprobing was necessary, stripping was performed by incubation in Tris-buffered saline (pH 6.7) containing 100 mM beta-mercaptoethanol, 2% SDS, at 54°C for 30 min.

Immunoreactive bands were normalized to β-actin levels using ImageJ 1.44p software. Values were given as relative units (RU). Each experiment was performed in triplicate.

2.8. Statistical Analysis. All data are presented as mean ± SEM. Statistical analysis was assessed by one-way ANOVA followed by Holm-Sidak multiple comparison. Analyses were performed using the Sigma Stat software (Jandel Scientific Corporation, San Rafael, CA, USA). P value < 0.05 was considered statistically significant.

3. Results

3.1. Pretreatment with Crocetin or AS101 Reduces CPM-Induced Follicle Loss. To assess the potential of crocetin as an attenuating agent against CPM toxicity, adult female mice were treated with a daily dose of 100 mg/kg crocetin for 15 days before administration of 100 mg/kg CPM. A group of adult female mice was treated with AS101 (10 µg/mouse) on alternate days beginning 15 days before CPM treatment. Quantification of the different follicle populations was carried out in the ovaries 1 week after CPM administration. As shown in Figure 1(a), mice receiving crocetin prior to CPM retained a number of primordial follicles larger than CPM alone and not significantly different from untreated controls. Quantification of primordial follicles also revealed that the crocetin effect was similar to AS101. A number of growing follicles in mice receiving crocetin or AS101 prior to CPM was significantly larger than CPM alone reaching values similar to untreated controls.

3.2. Crocetin and AS101 Treatments Rescue Fertility in CPM-Treated Mice. To confirm that preservation of primordial follicles observed in CPM-treated mice receiving crocetin or AS101 was associated with increased fertility, mice from each experimental group were mated for three rounds. At the time of mating, all females had normal oestrous cycles, had similar weight, and appeared healthy. Our data show that a single dose of 100 mg/kg CPM did not affect the reproductive capability of mice until the third round of mating. At this time, we obtained no litter from the CPM mice since they were unable to get pregnant after one week of caging with males. By contrast, CPM-treated mice receiving crocetin or AS101 got pregnant after all mating rounds and presented a litter size not significantly different from the control group (Figure 2).

3.3. Effects of Crocetin and AS101 on PI3K/AKT/FOXO3A Pathway. To search for molecular mechanisms underlying protective effects of crocetin, we hypothesized a potential effect on the PI3K/AKT/FOXO3A pathway underlying...
primordial follicle activation. By looking at the effects at protein expression level, we found that CPM increased the activated form of AKT protein (pAKT) phosphorylated by PI3K and the inactive form of FOXO3a (pFOXO3a) phosphorylated by pAKT. By contrast, crocetin and AS101 treatment results in reduction of both pAKT and pFOXO3a when compared with CPM alone (Figures 3(a) and 3(b)). However, crocetin effect was more pronounced than AS101 and similar to untreated control.

3.4. SIRT1 Protein and Its Regulator HuR Are Increased during the Early Response to CPM. To investigate the involvement of SIRT1 in the response to CPM, we conducted the first set of experiments in human granulosa cells aimed to analyse changes in mRNA levels of SIRT1 and HuR after 3 h, 6 h, and 12 h of PM exposure. At first, we carried out experiments in order to identify the minimum effective dose of PM, the active metabolite of CPM. After 72 h of treatment, proliferation was significantly reduced in human granulosa cells cultured in the presence of 50 μM PM. Since no further inhibition was observed at 100 μM PM, \( P < 0.001 \), we employed the dose of 50 μM PM in gene expression experiments. Then, we analysed the expression level of SIRT1 and of HuR in COV434 cells exposed to 50 μM PM for 3 h, 6 h, and 12 h. Both genes increased their expression level in a time-dependent manner, suggesting the activation of the OS response in this cell line (Figures 4(b) and 4(c)).

In the second set of experiment, mice received CPM and were sacrificed at 12 h and 24 h after CPM treatment. Our results show that SIRT1 protein level increased at 12 h and doubled its expression at 24 h after CPM treatment (Figure 5(a)). HuR protein increased at 12 h after CPM to decrease at 24 h (Figure 5(b)).
3.5. Crocetin and AS101 Prevent the SIRT1 Upregulation Induced by CPM. In the second set of experiments, we tested whether crocetin and AS101 act by modulating the early adaptive response regulated by SIRT1. Our data showed that crocetin treatment prevented the increased expression of SIRT1 induced by CPM treatment (Figure 6). Furthermore, mice receiving crocetin prior to CPM presented a SIRT1 expression level equivalent to untreated controls. AS101 induced a reduced activation of SIRT1 protein production in comparison to CPM treatment, but its levels were enhanced when compared to crocetin and untreated control mice.

3.6. Crocetin and AS101 Prevent CPM-Induced Changes in Mitochondrial Markers. To test whether the protective effect of crocetin was exerted throughout regulation of mitochondrial markers, we analysed the expression level of SIRT3, SOD2, and PGC1-alpha. Similar to SIRT1, SIRT3 increased at 24 h following CPM (Figure 7(a)). Crocetin treatment prevented the SIRT3 increase induced by CPM although SIRT3 amount was lower than that observed in untreated controls. AS101 treatment promoted a similar effect. Moreover, CPM was found to significantly reduce SOD2 protein. Both crocetin and AS101 treatments attenuated this effect although SOD2 level was lower than that observed in untreated controls (Figure 7(b)). Our results also showed that CPM mice presented lower levels of PGC1-alpha protein when compared with control whereas crocetin and AS101 induced a threefold increase of this protein in comparison to untreated controls (Figure 7(c)).

4. Discussion

Considering the increment in survival rates of cancer patients in their childhood or reproductive age, searching for fertoprotective agents is the main challenge in oncology practice. Here, we demonstrate for the first time that oral administration of crocetin, a natural carotenoid derivative and effective free radical scavenger, attenuates CPM-induced gonadotoxicity and modulates molecular pathways involved in the early ovarian response to this anticancer drug. These observations provide strong evidence that an imbalance of redox potential is the main factor underlying CPM-induced ovarian damage. Moreover, we outlined that crocetin effects at both molecular and biological levels resembled those by AS101, the most relevant candidate as a fertoprotective agent.

Crocetin, the main bioactive saffron compound [63, 64], is the hydrolysed active form of crocin, which is the most...
investigated saffron carotenoid. In comparison with crocin, crocetin is more rapidly absorbed in the intestinal tract and exhibits greater efficacy [65]. It is well established that the therapeutic effects of crocetin against some types of cancers, including breast cancer, have been pointed out [47, 48, 54–56, 66–69]. Crocetin acts in a dose-dependent manner in in vitro models [47, 55, 67, 68]. Oral administration of crocetin has been employed in research on mice aimed to investigate its effects against retinal damage [70] and tumour growth [56, 69]. Crocetin has also been administrated to healthy adult human volunteers, demonstrating that it is beneficial also in humans [71, 72]. Although only one paper reported the prevention by crocetin of CPM side effects on the bladder and liver [73], a plethora of publications reveals that crocetin can provide protection against OS induced by toxicants or underlying disorders in numerous organs, tissues, and cells [49–52, 74–78].

Our data show that crocetin protects primordial and growing follicles from CPM injury and the mechanism underlying the protective action of crocetin is similar to that of AS101. Crocetin treatment results in the reduction of the phosphorylated/activated form of AKT protein (pAKT) and the phosphorylated/inactive form of FOXO3a (pFOXO3a) when compared with CPM. According to our results, crocetin treatment was more effective in reducing the activation of the PI3K/AKT/FOXO3a pathway in response to CPM since pAKT and pFOXO3a levels were lower than that observed in AS101 although this difference did not result in higher efficacy in terms of follicle survival. Thus, it would be suggested that crocetin, similar to AS101, prevents dysregulation of follicle activation induced by CPM. Nevertheless, further investigation is needed to clarify whether crocetin, similar to AS101 [20], is able to reduce follicle apoptosis induced by CPM.

In addition to its role in follicle activation, FOXO3a is known to activate an antioxidant response when deacetylated by SIRT1. However, this function cannot be exerted when FOXO3a is phosphorylated by AKT. Thus, we can hypothesize that the increased levels of pFOXO3a in CPM ovaries may compromise the antioxidant response orchestrated by SIRT1.

SIRT1 plays a critical role in coordinating cellular response to stress, and SIRT1 levels are upregulated by cellular stressors, including metabolic, genotoxic, and oxidative stress [79]. Indeed, in our model of human granulosa cells sensitive to antiproliferative effects of CPM, Sirt1 and HuR transcription gradually increases with the same kinetics, demonstrating the involvement of SIRT1 in the early steps of cell response to CPM damage. This conclusion has been confirmed in the animal model where we observed that as

![Figure 4: SIRT1 and HuR mRNA increase after a PM treatment in human granulosa cell. (a) After 72 h of treatment, human granulosa cells cultured in the presence of 50 μM PM showed a significant reduction of proliferation. (b) SIRT1 and (c) HuR mRNA expression levels after 50 μM PM treatment were evaluated by performing a q-RT PCR. RNA18S was used as an endogenous control. Data represent means ± SEM. Experiments were done in triplicate (n = 3). **P < 0.01, and ***P < 0.001.](image-url)
Figure 5: CPM treatment induces an increase of SIRT1 and HuR. Protein analysis was conducted on ovaries from 8-week-old mice (*n* = 3, per experimental group) removed 12 or 24 hours after a single dose of CPM. Western blots of SIRT1 (a) and HuR (b) and representative images (c). Fold change is represented as a bar graph. Experiments were repeated three times with similar results. One-way ANOVA (*P* < 0.001), followed by multiple comparison by Holm-Sidak (**∗∗∗*P* < 0.001; **∗*P* < 0.05).

Figure 6: Crocetin and AS101 reduce CPM-induced activation of SIRT1 protein in the ovary. Protein analysis was conducted on ovaries from 8-week-old mice (*n* = 3, per experimental group) removed 24 hours after a single dose of CPM preceded or not by crocetin or AS101 pre-treatment. Western blots of SIRT1 (a) and representative images (b). Fold change is represented as a bar graph. Experiments were repeated three times with similar results. One Way ANOVA *P* < 0.001, followed by Multiple comparison by Holm-Sidak: **∗∗∗*P* < 0.001; **∗*P* < 0.05.
early as 12 h following CPM administration, the ovary activates an adaptive response based on upregulation of SIRT1 protein that peaks at 24 h. This pattern is preceded by upregulation of HuR which peaks at 12 h to decrease at 24 h indicating that in response to stress HuR may act transiently to stabilise SIRT1 transcripts prior to be degraded [80]. Nevertheless, other roles for HuR cannot be excluded. Posttranscriptional function of HuR has been described for a wide number of transcripts bearing AU-rich elements whose turnover is critical for cell fate [81–83].

Previous reports described a reduction of SIRT1 levels in rat ovaries in response to CPM and the protective role of caloric restriction associated with increased SIRT1 expression [84]. This is not in contrast with our results since we focused on the evaluation of the early response assessed before biological damage whereas the reduction of SIRT1 levels described elsewhere could be related to depletion of follicle population following CPM treatment. Moreover, SIRT1 has been recently involved in the regulation of bioenergetics metabolism during folliculogenesis. In this regard, Cinco et al., [85] observed that oocyte expression of SIRT1 is increasing during primordial follicle awkening together with a significant increase of NAD+ levels resulting from the activation of oxidative phosphorylation for energy supply during growth. Thus, the increased levels of ovarian SIRT1 during the early phase of CPM damage may be the cause or the effect of primordial follicle activation leading to the burnout effect.

Our data showed that both crocetin and AS101 prevented the increased expression of SIRT1 induced by CPM. This could be ascribed to their ability to counteract CPM-induced changes in the redox potential leading to SIRT1 recruitment. However, the observation that levels of SIRT1 in the two groups are not the same would suggest that crocetin and AS101 have a different ability to modulate ovarian
physiological environment, which influences SIRT1 expression. The hypothesis of the oxidative basis of CPM ovarian damage is supported by the finding that crocetin and AS101 prevented CPM-induced mitochondrial toxicity. In particular, crocetin and AS101 treatment counteracted the upregulation of the mitochondrial sirtuin SIRT3 induced by CPM. SIRT3 is considered a key coordinator of mitochondrial energy metabolism under stress conditions by directly targeting and modulating various processes [39–41] and downregulating mitochondrial protein synthesis [86]. Further evidence of OS and its mitochondrial basis are the downregulation of PGC1-α and SOD2 in CPM ovaries and the observation that these mitochondrial proteins severely increased their expression following crocetin and AS101 administration.

Therefore, it can be speculated that SIRT1 is recruited in order to regulate cell fate following CPM injury. In the experimental model proposed here, it seems to fail to orchestrate an efficient repair in concomitance with SIRT3, probably because its substrates, such as FOXO3a and PGC1-α, or downstream effectors, such as SOD2, are impaired. For these reasons, we propose that SIRT1 could be considered as a marker of CPM ovarian injury. Given its role as a sensor of damage and effector of cell fate, caution should be taken in proposing attenuating therapies based on SIRT1 targeting.

The inhibition of CPM-induced follicle loss by AS101 has been ascribed to its ability to inhibit AKT activation and reduce apoptosis in large growing follicles [20]. The finding that a potent antioxidant such as crocetin exerts similar effects on the PI3K/AKT/FOXO3A pathway suggests that AS101 may also act upstream to this pathway by preventing the OS burst induced by CPM. This hypothesis is also supported by the observation that, similar to crocetin, AS101 prevents the activation of OS sensors and mitochondrial toxicity induced by CPM. It is also important to consider that beneficial effects by both crocetin and AS101 may be ascribed to their effects on the whole ovarian microenvironment. In this regard, crocetin’s ability to increase diffusion of oxygen through the plasma can contribute to counteract CPM-induced inhibition of follicular microvascularization [87]. Moreover, anti-inflammatory properties are known for both these agents [50, 53, 88, 89] although these effects in the ovary need to be investigated.

The present study represents a contribution to previous evidence in animal models about the use of saffron bioactive molecules in the fertility field. Recent investigations have revealed that crocetin and its derivative crocin have beneficial effects on in vitro oocyte maturation, sperm quality, and fertilization [90–94]. Moreover, crocin has been described to protect male gonad against CPM toxicity [46].

In conclusion, we speculate that the ovarian adaptive response to CPM consists in a complex network involving oxidative stress, SIRT1, and mitochondrial damage (Figure 8). Finally, due to its efficacy in the animal model and its anticancer properties and low toxicity in humans, this work demonstrates for the first time that crocetin presents all necessary properties to be explored in clinical trials.
the characteristics required for a natural fertoprotective agent to be included in future clinical studies.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Acknowledgments
The funds for this work were provided by the Department of Life, Health and Environmental Sciences, University of L’Aquila (RIA 2013-2016).

References
[1] J. M. Levine, J. F. Kelvin, G. P. Quinn, and C. R. Gracia, “Infertility in reproductive-age female cancer survivors,” Cancer, vol. 121, no. 10, pp. 1532–1539, 2015.
[2] A. W. Loren, P. B. Mangu, L. N. Beck et al., “Fertility preservation for patients with cancer: American society of clinical oncology clinical practice guideline update,” Journal of Clinical Oncology, vol. 31, no. 19, pp. 2500–2510, 2013.
[3] T. K. Woodruff, “Oncofertility: a grand collaboration between reproductive medicine and oncology,” Reproduction, vol. 150, no. 3, pp. S1–S10, 2015.
[4] H. A. Parlakgumus, E. B. Kilicdag, F. A. Bolat, B. Haydardedeoglu, and A. Parlakgumus, “GnRH agonists and antagonists in rescue for cyclophosphamide-induced ovarian damage: friend or foe?,” Archives of Gynecology and Obstetrics, vol. 291, no. 6, pp. 1403–1410, 2015.
[5] M. Lambertini, F. Poggio, A. Levaggi, and L. Del Mastro, “Protecting oocytes during chemotherapy through gonad suppression: a systematic review and meta-analysis,” Obstetrics and Gynecology, vol. 126, no. 4, p. 901, 2015.
[6] R. Leonard, D. Adamson, G. Bertelli et al., “GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial,” Annals of Oncology, vol. 28, no. 8, pp. 1811–1816, 2017.
[7] H. Roness, L. Kalich-Philosoph, and D. Meirow, “Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents,” Human Reproduction Update, vol. 20, no. 5, pp. 759–774, 2014.
[8] H. Roness, O. Kashi, and D. Meirow, “Prevention of chemotherapy-induced ovarian damage,” Fertility and Sterility, vol. 105, no. 1, pp. 20–29, 2016.
[9] D. Meirow, H. Lewis, D. Nugent, and M. Epstein, “Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool,” Human Reproduction, vol. 14, no. 7, pp. 1903–1907, 1999.
[10] D. Meirow, M. Epstein, H. Lewis, D. Nugent, and R. G. Gosden, “Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations,” Human Reproduction, vol. 16, no. 4, pp. 632–637, 2001.
[11] O. Oktem and K. Oktay, “A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve,” Cancer Research, vol. 67, no. 21, pp. 10159–10162, 2007.
[12] I. Ben-Aharon and R. Shalgi, “What lies behind chemotherapy-induced ovarian toxicity?,” Reproduction, vol. 144, no. 2, pp. 153–163, 2012.
[13] O. M. Colvin, “An overview of cyclophosphamide development and clinical applications,” Current Pharmaceutical Design, vol. 5, no. 8, pp. 555–560, 1999.
[14] G. E. Katsifis and A. G. Tzioufas, “Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide,” Lupus, vol. 13, no. 9, pp. 673–678, 2004.
[15] M. A. Dooley and R. Nair, “Therapy insight: preserving fertility in cyclophosphamide-treated patients with rheumatic disease,” Nature Clinical Practice. Rheumatology, vol. 4, no. 5, pp. 250–257, 2008.
[16] S. K. Petrillo, P. Desmeules, T. Q. Truong, and P. J. Devine, “Detection of DNA damage in oocytes of small ovarian follicles following phosphoramide mustard exposures of cultured rodent ovaries in vitro,” Toxicology and Applied Pharmacology, vol. 253, no. 2, pp. 94–102, 2011.
[17] S. Ganesan and A. F. Keating, “Phosphoramide mustard exposure induces DNA adduct formation and the DNA damage repair response in rat ovarian granulosa cells,” Toxicology and Applied Pharmacology, vol. 282, no. 3, pp. 252–258, 2015.
[18] S. Ganesan and A. F. Keating, “The ovarian DNA damage repair response is induced prior to phosphoramide mustard-induced follicle depletion, and ataxia telangiectasia mutated inhibition prevents PM-induced follicle depletion,” Toxicology and Applied Pharmacology, vol. 292, pp. 65–74, 2016.
[19] G. Bedoschi, P. A. Navarro, and K. Oktay, “Chemotherapy-induced damage to ovary: mechanisms and clinical impact,” Future Oncology, vol. 12, no. 19, pp. 2333–2344, 2016.
[20] L. Kalich-Philosoph, H. Roness, A. Carmely et al., “Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility,” Science Translational Medicine, vol. 5, no. 185, article 185ra62, 2013.
[21] A. Makker, M. M. Goel, and A. A. Mahdi, “PI3K/PDK1/Akt and TSC/mTOR signaling pathways, ovarian dysfunction, and infertility: an update,” Journal of Molecular Endocrinology, vol. 53, no. 3, pp. R103–R118, 2014.
[22] M. Hayun, Y. Naor, M. Weil et al., “The immunomodulator AS101 induces growth arrest and apoptosis in multiple myeloma: association with the Akt/survivin pathway,” Biochemical Pharmacology, vol. 72, no. 11, pp. 1423–1431, 2006.
[23] P. J. Devine, S. D. Perreault, and U. Luderer, “Roles of reactive oxygen species and antioxidants in ovarian toxicity,” Biology of Reproduction, vol. 86, no. 2, p. 27, 2012.
[24] U. Luderer, “Ovarian toxicity from reactive oxygen species,” Vitamins and Hormones, vol. 94, pp. 99–127, 2014.
[25] M. Tsi-Turton, B. T. Luong, Y. Tan, and U. Luderer, “Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion,” Toxicological Sciences, vol. 98, no. 1, pp. 216–230, 2007.
[26] D. O. Saleh and D. F. Mansour, “Ovario-protective effects of genistein against cyclophosphamide toxicity in rats: role of anti-mullerian hormone and oestriol,” European Journal of Pharmacology, vol. 789, pp. 163–171, 2016.
[27] N. A. Yener, O. Sinanoglu, E. Ilter et al., “Effects of spirulina on cyclophosphamide-induced ovarian toxicity in rats: biochemical and histomorphometric evaluation of the ovary,”
B. J. Morris, "Seven sirtuins for seven deadly diseases of aging," *Free Radical Biology & Medicine*, vol. 56, pp. 133–171, 2013.

Y. S. Hori, A. Kunoo, R. Hosoda, and Y. Horio, "Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress," *PLoS One*, vol. 8, no. 9, article e73875, 2013.

J. W. Hwang, H. Yao, S. Caiot, I. K. Sundar, and I. Rahman, "Redox regulation of SIRT1 in inflammation and cellular senescence," *Free Radical Biology & Medicine*, vol. 61, pp. 95–110, 2013.

A. Salminen, K. Kaarniranta, and A. Kauppinen, "Crosstalk between oxidative stress and SIRT1: impact on the aging process," *International Journal of Molecular Sciences*, vol. 14, no. 2, pp. 3834–3859, 2013.

L. R. Saunders and E. Verdin, "Sirtuins: critical regulators at the crossroads between cancer and aging," *Oncogene*, vol. 26, no. 37, pp. 5489–5504, 2007.

G. Di Emidio, S. Falone, M. Vitti et al., "SIRT1 signalling protects mouse oocytes against oxidative stress and is deregulated during aging," *Human Reproduction*, vol. 29, no. 9, pp. 2006–2017, 2014.

C. Tatone, G. Di Emidio, M. Vitti et al., "Sirtuin functions in female fertility: possible role in oxidative stress and aging," *Oxidative Medicine and Cellular Longevity*, vol. 2015, Article ID 659687, 11 pages, 2015.

J. R. Revollo and X. Li, "The ways and means that fine tune Sirt1 activity," *Trends in Biochemical Sciences*, vol. 38, no. 3, pp. 160–167, 2013.

B. M. Hock and A. Kralli, "Transcriptional control of mitochondrial biogenesis and function," *Annual Review of Physiology*, vol. 71, pp. 177–203, 2009.

M. M. Chishita, J. Y. Park, J. M. Burnskeisk, J. C. Barrett, and I. Horikawa, "Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins," *Molecular Biology of the Cell*, vol. 16, no. 10, pp. 4623–4635, 2005.

J. Bremmoehl and A. Hoeflich, "Dual control of mitochondrial biogenesis by sirtuin 1 and sirtuin 3," *Mitochondrion*, vol. 13, no. 6, pp. 755–761, 2013.

P. Parhgar, I. Solanka, M. L. Mansuri, and M. S. Parhgar, "Mitochondrial sirtuins: emerging roles in metabolic regulations, energy homeostasis and diseases," *Experimental Gerontology*, vol. 61, pp. 130–141, 2015.

D. M. Salvadori, L. R. Ribeiro, M. D. Oliveira, C. A. Pereira, and W. Bećak, "The protective effect of ß-carotene on genotoxicity induced by cyclophosphamide," *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*, vol. 265, no. 2, pp. 237–244, 1992.

D. N. Tripathi and G. B. Jena, "Astaxanthin inhibits cytotoxic and genotoxic effects of cyclophosphamide in mice germ cells," *Toxicology*, vol. 248, no. 2, pp. 96–103, 2008.

S. Sadir, S. Deveci, A. Korkmaz, and S. Oter, "Alpha-tocopherol, beta-carotene and melatonin administration protects cyclophosphamide-induced oxidative damage to bladder tissue in rats," *Cell Biochemistry and Function*, vol. 25, no. 5, pp. 521–526, 2007.

S. Jnaneswari, M. Hemshekhar, M. S. Santhosh et al., "Crocin, a dietary colorant, mitigates cyclophosphamide-induced organ toxicity by modulating antioxidant status and inflammatory cytokines," *The Journal of Pharmacy and Pharmacology*, vol. 65, no. 4, pp. 604–614, 2013.

Z. Bakhtiar, R. Shahrrooz, A. Ahmadi, and L. Zarei, "Evaluation of antioxidant effects of crocin on sperm quality in cyclophosphamide treated adult mice," *Veterinary Research Forum*, vol. 5, no. 3, pp. 213–218, 2014.

W. G. Guthiel, G. Reed, A. Ray, S. Anant, and A. Dhar, "Crocetin: an agent derived from saffron for prevention and therapy for cancer," *Current Pharmaceutical Biotechnology*, vol. 13, no. 1, pp. 173–179, 2012.

S. Samarghandian and A. Borji, "Anticarcinogenic effect of saffron (*Crocus sativus* L.) and its ingredients," *Pharmacognosy Research*, vol. 6, no. 2, pp. 99–107, 2014.

M. Venkatraman, D. Konga, R. Peramaiani, E. Ganapathy, and S. Dhanapal, "Reduction of mitochondrial oxidative damage and improved mitochondrial efficiency by administration of crocetin against benzo[a]pyrene induced experimental animals," *Biological & Pharmaceutical Bulletin*, vol. 31, no. 9, pp. 1639–1645, 2008.

K. N. Nami, Y. M. Park, H. J. Jung et al., "Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells," *European Journal of Pharmacology*, vol. 648, no. 1–3, pp. 110–116, 2010.

F. Yoshino, A. Yoshida, N. Umiaga, K. Kubo, and M. C. Lee, "Crocetin reduces the oxidative stress induced reactive oxygen species in the stroke-prone spontaneously hypertensive rats (SHRSPs) brain," *Journal of Clinical Biochemistry and Nutrition*, vol. 49, no. 3, pp. 182–187, 2011.

R. Yang, L. Yang, X. Shen et al., "Suppression of NF-kB pathway by crocetin contributes to attenuation of lipopolysaccharide-induced acute lung injury in mice," *European Journal of Pharmacology*, vol. 674, no. 2–3, pp. 391–396, 2012.

M. H. Boskabady and T. Forhkonhede, "Antinflammatory, antioxidant, and immunomodulatory effects of *Crocus sativus* L. and its main constituents," *Phytotherapy Research*, vol. 30, no. 7, pp. 1072–1094, 2016.

A. Bolhassani, A. Khavari, and S. Z. Batheia, "Saffron and natural carotenoids: biochemical activities and anti-tumor effects," *Biocimica et Biophysica Acta (BBA)-Reviews on Cancer*, vol. 1845, no. 1, pp. 20–30, 2014.

S. H. Kim, J. M. Lee, S. C. Kim, C. B. Park, and P. C. Lee, "Proposed cytotoxic mechanisms of the saffron (*Crocus sativus* L.) and its main constituents," *Phytotherapy Research*, vol. 30, no. 7, pp. 1072–1094, 2016.

C. Festuccia, A. Mancini, G. L. Gravina et al., "Antitumor effects of saffron-derived carotenoids in prostate cancer cell models," *BioMed Research International*, vol. 2014, Article ID 135048, 12 pages, 2014.

A. Yulkes, G. Bildik, F. Senbabaooglu et al., "The magnitude of gonadotoxicity of chemotherapy drugs on ovarian follicles and granulosa cells varies depending upon the category of the drugs and the type of granulosa cells," *Human Reproduction*, vol. 30, no. 12, pp. 2926–2935, 2015.
[58] A. M. Sánchez, M. Carmona, S. A. Ordoudi, M. Z. Tsimidou, and G. L. Alonso, “Kinetics of individual crocetin ester degradation in aqueous extracts of saffron (Crocus sativus L.) upon thermal treatment in the dark,” Journal of Agricultural and Food Chemistry, vol. 56, no. 5, pp. 1627–1637, 2008.

[59] A. M. Sánchez, M. Carmona, A. Zalacain, J. M. Carot, J. M. Jabaloyes, and G. L. Alonso, “Rapid determination of crocetin esters and picrocrocin from saffron spice (Crocus sativus L.) using UV-visible spectrophotometry for quality control,” Journal of Agricultural and Food Chemistry, vol. 56, no. 9, pp. 3167–3175, 2008.

[60] T. Pedersen and H. Peters, “Proposal for a classification of oocytes and follicles in the mouse ovary,” Journal of Reproduction and Fertility, vol. 17, no. 3, pp. 555–557, 1968.

[61] J. L. Tilly, “Ovarian follicle counts—not as simple as 1, 2, 3,” Reproductive Biology and Endocrinology, vol. 1, p. 11, 2003.

[62] H. Zhang, M. Vollmer, M. De Geyter et al., “Characterization of an immortalized human granulosa cell line (COV34),” Molecular Human Reproduction, vol. 6, no. 2, pp. 146–153, 2000.

[63] L. Xi, Z. Qian, P. Du, and J. Fu, “Pharmacokinetic properties of crocin (crocetin digentiobiose ester) following oral administration in rats,” Phytomedicine, vol. 14, no. 9, pp. 633–636, 2007.

[64] A. Asai, T. Nakano, M. Takahashi, and A. Nagao, “Orally administered crocin and crocins are absorbed into blood plasma as crocetin and its glucuronide conjugates in mice,” Journal of Agricultural and Food Chemistry, vol. 53, no. 18, pp. 7302–7306, 2005.

[65] B. Amin, A. Nakhzad, and H. Hossein-zadeh, “Evaluation of the antidepressant-like effects of acute and sub-acute administration of crocin and crocetin in mice,” Avicenna Journal of Phytomedicine, vol. 5, no. 5, pp. 458–468, 2015.

[66] A. M. D’Alessandro, A. Mancini, A. R. Lizzi et al., “Crocus sativus stigma extract and its major constituent crocin possess significant antiproliferative properties against human prostate cancer,” Nutrition and Cancer, vol. 65, no. 6, pp. 930–942, 2013.

[67] Y. J. Zhong, F. Shi, X. L. Zheng et al., “Crocetin induces cytotoxicity and enhances vincristine-induced cancer cell death via p53-dependent and -independent mechanisms,” Acta Pharmacologica Sinica, vol. 32, no. 12, pp. 1529–1536, 2011.

[68] A. Zhang and J. Li, “Crocetin shifts autophagic cell survival to death of breast cancer cells in chemotherapy,” Tumour Biology, vol. 39, no. 3, article 1010428317694536, 2017.

[69] M. Sajjadi and Z. Bathia, “Comparative study on the preventive effect of saffron carotenoids, crocin and crocetin, in NMU-induced breast cancer in rats,” Cell Journal, vol. 19, no. 1, pp. 94–101, 2017.

[70] Y. Ohno, T. Nakanishi, N. Umigai, K. Tsuruma, M. Shimazawa, and H. Hara, “Oral administration of crocetin prevents inner retinal damage induced by N-methyl-D-aspartate in mice,” European Journal of Pharmacology, vol. 690, no. 1–3, pp. 84–89, 2012.

[71] H. Mizuma, M. Tanaka, S. Nozaki et al., “Daily oral administration of crocetin attenuates physical fatigue in human subjects,” Nutrition Research, vol. 29, no. 3, pp. 145–150, 2009.

[72] N. Umigai, K. Murakami, M. V. Ullt et al., “The pharmacokinetic profile of crocetin in healthy adult human volunteers after a single oral administration,” Phytomedicine, vol. 18, no. 7, pp. 575–578, 2011.

[73] S. C. Nair, K. R. Panikkar, and R. K. Parthod, “Protective effects of crocetin on the bladder toxicity induced by cyclophosphamide,” Cancer Biotherapy, vol. 8, no. 4, pp. 339–343, 1993.

[74] A. Mancini, J. Serrano-Díaz, E. Nava et al., “Crocetin, a carotenoid derived from saffron (Crocus sativus L.), improves acetylcholine-induced vascular relaxation in hypertension,” Journal of Vascular Research, vol. 51, no. 5, pp. 393–404, 2014.

[75] Y. Wang, J. Sun, C. Liu, and C. Fang, “Protective effects of crocetin pretreatment on myocardial injury in an ischemia/reperfusion rat model,” European Journal of Pharmacology, vol. 741, pp. 290–296, 2014.

[76] S. Higashino, Y. Sasaki, J. C. Giddings et al., “Crocetin, a carotenoid from Gardenia jasminoides Ellis, protects against hypertension and cerebral thrombogenesis in stroke-prone spontaneously hypertensive rats,” Phytotherapy Research, vol. 28, no. 9, pp. 1315–1319, 2014.

[77] C. Zhou, W. Bai, Q. Chen et al., “Protective effect of crocetin against burn-induced intestinal injury,” The Journal of Surgical Research, vol. 198, no. 1, pp. 99–107, 2015.

[78] K. Niska, M. J. Santos-Martinez, M. W. Radomski, and I. Inkiewicz-Stepniak, “CuO nanoparticles induce apoptosis by impairing the antioxidant defense and detoxification systems in the mouse hippocampal HT22 cell line: protective effect of crocetin,” Toxicology In Vitro, vol. 29, no. 4, pp. 663–671, 2015.

[79] M. Buler, U. Andersson, and J. Hakkola, “Who watches the watchmen? Regulation of the expression and activity of sir-2,” The FASEB Journal, vol. 30, no. 12, pp. 3942–3960, 2016.

[80] R. Raynes, J. Brunquell, and S. D. Westerheide, “Stress inducibility of sirt1 and its role in cytoprotection and cancer,” Genes & Cancer, vol. 4, no. 3–4, pp. 172–182, 2013.

[81] N. S. Levy, S. Chung, H. Furneaux, and A. P. Levy, “Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR,” The Journal of Biological Chemistry, vol. 273, no. 11, pp. 6417–6423, 1998.

[82] K. Abdelmohsen, R. Pullmann Jr., A. Lal et al., “Phosphorylation of HuR by Chk2 regulates SIRT1 expression,” Molecular Cell, vol. 25, no. 4, pp. 543–557, 2007.

[83] C. Zucal, V. D’Agostino, R. LoBredo et al., “Targeting the multifaceted HuR protein, benefits and caveats,” Current Drug Targets, vol. 16, no. 5, pp. 499–515, 2015.

[84] Y. Xiang, J. Xu, L. Li et al., “Calorie restriction increases primordial follicle reserve in mature female chemotherapy-treated rats,” Gene, vol. 493, no. 1, pp. 77–82, 2012.

[85] R. Cinco, M. A. Digman, E. Gratton, and U. Luderer, “Spatial characterization of bioenergetics and metabolism of primordial to preovulatory follicles in whole ex vivo murine ovary,” Biology of Reproduction, vol. 95, no. 6, pp. 1–12, 2016.

[86] Y. Yang, H. Cimen, M. J. Han et al., “NAD+-dependent deacetylase SIRT3 regulates mitochondrial protein synthesis by deacetylation of the ribosomal protein MRPL10,” The Journal of Biological Chemistry, vol. 285, no. 7, pp. 578–589, 2010.

[87] K. Ezo, N. Murata, A. Yabuuchi et al., “Long-term adverse effects of cyclophosphamide on follicular growth and angiogenesis in mouse ovaries,” Reproductive Biology, vol. 14, no. 3, pp. 238–242, 2014.
[88] M. Brodsky, G. Halpert, M. Albeck, and B. Sredni, “The anti-inflammatory effects of the tellurium redox modulating compound, AS101, are associated with regulation of NFκB signaling pathway and nitric oxide induction in macrophages,” *Journal of Inflammation*, vol. 7, no. 1, p. 3, 2010.

[89] D. Ling, B. Liu, S. Jawad et al., “The tellurium redox immunomodulating compound AS101 inhibits IL-1β-activated inflammation in the human retinal pigment epithelium,” *The British Journal of Ophthalmology*, vol. 97, no. 7, pp. 934–938, 2013.

[90] E. Mokhber Maleki, H. Eimani, M. R. Bigdeli et al., “A comparative study of saffron aqueous extract and its active ingredient, crocin on the in vitro maturation, in vitro fertilization, and in vitro culture of mouse oocytes,” *Taiwanese Journal of Obstetrics & Gynecology*, vol. 53, no. 1, pp. 21–25, 2014.

[91] E. Mokhber Maleki, H. Eimani, M. R. Bigdeli, A. Golkar Narenji, and R. Abedi, “Effects of crocin supplementation during in vitro maturation of mouse oocytes on glutathione synthesis and cytoplasmic maturation,” *International Journal of Fertility & Sterility*, vol. 10, no. 1, pp. 53–61, 2016.

[92] V. Sapanidou, I. Taitzoglou, I. Tsakmakidis et al., “Antioxidant effect of crocin on bovine sperm quality and in vitro fertilization,” *Theriogenology*, vol. 84, no. 8, pp. 1273–1282, 2015.

[93] V. Sapanidou, I. Taitzoglou, I. Tsakmakidis et al., “Protective effect of crocetin on bovine spermatozoa against oxidative stress during in vitro fertilization,” *Andrology*, vol. 4, no. 6, pp. 1138–1149, 2016.

[94] G. Zullo, C. De Canditiis, M. E. Pero et al., “Crocetin improves the quality of in vitro-produced bovine embryos: implications for blastocyst development, cryotolerance, and apoptosis,” *Theriogenology*, vol. 86, no. 8, pp. 1879–1885, 2016.
